Difference between revisions of "Editing test page"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m
m
Line 10: Line 10:
 
|-
 
|-
 
|colspan="2" style="background-color:#66FF66"|'''[[Tutorial#Regimens|Regimens]]: {{#ask: [[Regimen::+]] |?Regimen |limit=10000|format=sum}}'''
 
|colspan="2" style="background-color:#66FF66"|'''[[Tutorial#Regimens|Regimens]]: {{#ask: [[Regimen::+]] |?Regimen |limit=10000|format=sum}}'''
−
|colspan="2" style="background-color:#66CCFF"|'''Regimen variants: {{#ask: [[Variant::+]] |?Variant |limit=10000|format=sum}}'''
+
|colspan="2" style="background-color:#66CCFF"|'''[[Tutorial#Variant|Regimen variants]]: {{#ask: [[Variant::+]] |?Variant |limit=10000|format=sum}}'''
 
|-
 
|-
 
|colspan="4" style="background-color:#505050"|
 
|colspan="4" style="background-color:#505050"|
 
|-
 
|-
−
|style="background-color:#F0F0F0"|'''[https://hemonc.org/w/index.php?title=Main_Page&mobileaction=toggle_view_desktop Desktop Version]'''
+
|style="color:white;background-color:#3182bd"|[[#solidtumors|Solid Tumors]]  
−
|style="background-color:#F0F0F0"|'''[https://hemonc.org/w/index.php?title=Main_Page&mobileaction=toggle_view_mobile Mobile Version]'''
+
|style="color:white;background-color:#de2d26"|[[#malignantheme|Malignant Heme]]
−
|style="background-color:#F0F0F0"|'''[[How to add HemOnc.org to your home screen | Mobile shortcut]]'''
+
|style="color:white;background-color:#31a354"|[[#otherheme|Other Heme]]
−
|style="background-color:#F0F0F0"|'''[[Hematology Oncology Fellowship Programs Directory|Fellowship programs]]'''
+
|style="color:white;background-color:#756bb1"|[[#transplant|Transplant]]
 
|-
 
|-
 
|colspan="4" background-color:#FFFFE0"|<big>[[Editorial Board]]</big>
 
|colspan="4" background-color:#FFFFE0"|<big>[[Editorial Board]]</big>
Line 26: Line 26:
 
|style="background-color:#F0F0F0"|[[:Category:General reference pages|General reference]]
 
|style="background-color:#F0F0F0"|[[:Category:General reference pages|General reference]]
 
|-
 
|-
−
|[[#solidtumors|Solid Tumors]]  
+
|'''[https://hemonc.org/w/index.php?title=Main_Page&mobileaction=toggle_view_desktop Desktop Version]'''
−
|[[#malignantheme|Malignant Hematology]]
+
|'''[https://hemonc.org/w/index.php?title=Main_Page&mobileaction=toggle_view_mobile Mobile Version]'''
−
|[[#otherheme|Other Hematology]]
+
|'''[[How to add HemOnc.org to your home screen | Mobile shortcut]]'''
 +
|'''[[Hematology Oncology Fellowship Programs Directory|Fellowship programs]]'''
 
|}  
 
|}  
  
Line 36: Line 37:
 
<span id="solidtumors"></span>
 
<span id="solidtumors"></span>
 
{| border="1" style="text-align:center; margin-left: auto; margin-right: auto; font-weight: bold; width: 100%;"
 
{| border="1" style="text-align:center; margin-left: auto; margin-right: auto; font-weight: bold; width: 100%;"
−
!colspan="4" align="center" style="color:white; font-size:150%; background-color:#00008B"| '''Solid Tumors'''
+
!colspan="4" align="center" style="color:white; font-size:150%; background-color:#3182bd"| '''Solid Tumors'''
 
|-
 
|-
−
|colspan="4" style="background-color:#93cdff"|'''Breast Oncology'''
+
|colspan="4" style="background-color:#9ecae1"|'''Breast Oncology'''
 
|-
 
|-
−
|colspan="2" style="background-color:#F0F8FF"|[[Breast cancer]]
+
|colspan="2" style="background-color:#deebf7"|[[Breast cancer]]
−
|colspan="2" style="background-color:#F0F8FF"|[[Breast cancer, HER-2 positive]]
+
|colspan="2" style="background-color:#deebf7"|[[Breast cancer, HER-2 positive]]
 
|-
 
|-
−
|colspan="4" style="background-color:#93cdff"|'''Dermatologic Oncology'''
+
|colspan="4" style="background-color:#9ecae1"|'''Dermatologic Oncology'''
 
|-
 
|-
−
|style="background-color:#F0F8FF"|[[Melanoma]]  
+
|style="background-color:#deebf7"|[[Melanoma]]  
−
|style="background-color:#F0F8FF"|[[Basal cell and squamous cell skin cancer | Skin, basal & squamous cancer]]
+
|style="background-color:#deebf7"|[[Basal cell and squamous cell skin cancer | Skin, basal & squamous cancer]]
−
|style="background-color:#F0F8FF"|[[Merkel cell carcinoma]]  
+
|style="background-color:#deebf7"|[[Merkel cell carcinoma]]  
−
|style="background-color:#F0F8FF"|
+
|style="background-color:#deebf7"|
 
|-
 
|-
−
|colspan="4" style="background-color:#93cdff"|'''Endocrine Oncology'''
+
|colspan="4" style="background-color:#9ecae1"|'''Endocrine Oncology'''
 
|-
 
|-
−
|style="background-color:#F0F8FF"|[[Germ cell tumors]]
+
|style="background-color:#deebf7"|[[Germ cell tumors]]
−
|style="background-color:#F0F8FF"|[[Neuroendocrine tumors]]
+
|style="background-color:#deebf7"|[[Neuroendocrine tumors]]
−
|style="background-color:#F0F8FF"|[[Thyroid cancer]]
+
|style="background-color:#deebf7"|[[Thyroid cancer]]
−
|style="background-color:#F0F8FF"|
+
|style="background-color:#deebf7"|
 
|-
 
|-
−
|colspan="4" style="background-color:#93cdff"|'''Gastrointestinal Oncology'''
+
|colspan="4" style="background-color:#9ecae1"|'''Gastrointestinal Oncology'''
 
|-
 
|-
−
|style="width: 25%; background-color:#F0F8FF"|[[Anal cancer]]
+
|style="width: 25%; background-color:#deebf7"|[[Anal cancer]]
−
|style="width: 25%; background-color:#F0F8FF"|[[Colon cancer]]
+
|style="width: 25%; background-color:#deebf7"|[[Colon cancer]]
−
|style="width: 25%; background-color:#F0F8FF"|[[Esophageal cancer]]
+
|style="width: 25%; background-color:#deebf7"|[[Esophageal cancer]]
−
|style="width: 25%; background-color:#F0F8FF"|[[Gastric cancer]]
+
|style="width: 25%; background-color:#deebf7"|[[Gastric cancer]]
 
|-
 
|-
−
|style="width: 25%; background-color:#F0F8FF"|[[Gastrointestinal stromal tumor|Gastrointestinal stromal tumor (GIST)]]
+
|style="width: 25%; background-color:#deebf7"|[[Gastrointestinal stromal tumor|Gastrointestinal stromal tumor (GIST)]]
−
|style="width: 25%; background-color:#F0F8FF"|[[Hepatobiliary cancer]]
+
|style="width: 25%; background-color:#deebf7"|[[Hepatobiliary cancer]]
−
|style="width: 25%; background-color:#F0F8FF"|[[Pancreatic cancer]]  
+
|style="width: 25%; background-color:#deebf7"|[[Pancreatic cancer]]  
−
|style="width: 25%; background-color:#F0F8FF"|[[Rectal cancer]]
+
|style="width: 25%; background-color:#deebf7"|[[Rectal cancer]]
 
|-
 
|-
−
|colspan="4" style="background-color:#93cdff"|'''Genitourinary Oncology'''
+
|colspan="4" style="background-color:#9ecae1"|'''Genitourinary Oncology'''
 
|-
 
|-
−
|style="background-color:#F0F8FF"|[[Bladder cancer]]
+
|style="background-color:#deebf7"|[[Bladder cancer]]
−
|style="background-color:#F0F8FF"|[[Germ cell tumors]]
+
|style="background-color:#deebf7"|[[Germ cell tumors]]
−
|style="background-color:#F0F8FF"|[[Penile cancer]]
+
|style="background-color:#deebf7"|[[Penile cancer]]
−
|style="background-color:#F0F8FF"|[[Prostate cancer]]
+
|style="background-color:#deebf7"|[[Prostate cancer]]
 
|-
 
|-
−
|style="background-color:#F0F8FF"|[[Renal cancer|Renal cancer (RCC)]]
+
|style="background-color:#deebf7"|[[Renal cancer|Renal cancer (RCC)]]
−
|style="background-color:#F0F8FF"|[[Testicular cancer]]
+
|style="background-color:#deebf7"|[[Testicular cancer]]
−
|style="background-color:#F0F8FF"|
+
|style="background-color:#deebf7"|
−
|style="background-color:#F0F8FF"|
+
|style="background-color:#deebf7"|
 
|-
 
|-
−
|colspan="4" style="background-color:#93cdff"|'''Gynecologic Oncology'''
+
|colspan="4" style="background-color:#9ecae1"|'''Gynecologic Oncology'''
 
|-
 
|-
−
|style="background-color:#F0F8FF"|[[Cervical cancer]]
+
|style="background-color:#deebf7"|[[Cervical cancer]]
−
|style="background-color:#F0F8FF"|[[Germ cell tumors]]
+
|style="background-color:#deebf7"|[[Germ cell tumors]]
−
|style="background-color:#F0F8FF"|[[Ovarian cancer]]
+
|style="background-color:#deebf7"|[[Ovarian cancer]]
−
|style="background-color:#F0F8FF"|[[Uterine cancer]]
+
|style="background-color:#deebf7"|[[Uterine cancer]]
 
|-
 
|-
−
|colspan="4" style="background-color:#93cdff"|'''Head & Neck Oncology'''
+
|colspan="4" style="background-color:#9ecae1"|'''Head & Neck Oncology'''
 
|-
 
|-
−
|colspan="2" style="background-color:#F0F8FF"|[[Head and neck cancer]]
+
|colspan="2" style="background-color:#deebf7"|[[Head and neck cancer]]
−
|colspan="2" style="background-color:#F0F8FF"|[[Thyroid cancer]]
+
|colspan="2" style="background-color:#deebf7"|[[Thyroid cancer]]
 
|-
 
|-
−
|colspan="4" style="background-color:#93cdff"|'''Neuro-Oncology'''
+
|colspan="4" style="background-color:#9ecae1"|'''Neuro-Oncology'''
 
|-
 
|-
−
|style="background-color:#F0F8FF"|[[Central nervous system (CNS) cancer]]
+
|style="background-color:#deebf7"|[[Central nervous system (CNS) cancer]]
−
|style="background-color:#F0F8FF"|[[Glioblastoma]]
+
|style="background-color:#deebf7"|[[Glioblastoma]]
−
|style="background-color:#F0F8FF"|[[CNS leukemia]]
+
|style="background-color:#fee0d2"|[[CNS leukemia]]
−
|style="background-color:#F0F8FF"|[[CNS lymphoma]]
+
|style="background-color:#fee0d2"|[[CNS lymphoma]]
 
|-
 
|-
−
|colspan="4" style="background-color:#93cdff"|'''Pediatric Oncology'''
+
|colspan="4" style="background-color:#9ecae1"|'''Pediatric Oncology'''
 
|-
 
|-
−
|colspan="4" style="background-color:#F0F8FF"|[[Neuroblastoma]]
+
|colspan="4" style="background-color:#deebf7"|[[Neuroblastoma]]
 
|-
 
|-
−
|colspan="4" style="background-color:#93cdff"|'''Sarcoma'''
+
|colspan="4" style="background-color:#9ecae1"|'''Sarcoma'''
 
|-
 
|-
−
|style="background-color:#F0F8FF"|[[Bone cancer]]  
+
|style="background-color:#deebf7"|[[Bone cancer]]  
−
|style="background-color:#F0F8FF"|[[Ewing's sarcoma]]
+
|style="background-color:#deebf7"|[[Ewing's sarcoma]]
−
|style="background-color:#F0F8FF"|[[Gastrointestinal stromal tumor|Gastrointestinal stromal tumor (GIST)]]
+
|style="background-color:#deebf7"|[[Gastrointestinal stromal tumor|Gastrointestinal stromal tumor (GIST)]]
−
|style="background-color:#F0F8FF"|[[Osteosarcoma]]
+
|style="background-color:#deebf7"|[[Osteosarcoma]]
 
|-
 
|-
−
|style="background-color:#F0F8FF"|[[Sarcoma]]  
+
|style="background-color:#deebf7"|[[Sarcoma]]  
−
|style="background-color:#F0F8FF"|
+
|style="background-color:#deebf7"|
−
|style="background-color:#F0F8FF"|
+
|style="background-color:#deebf7"|
−
|style="background-color:#F0F8FF"|
+
|style="background-color:#deebf7"|
 
|-
 
|-
−
|colspan="4" style="background-color:#93cdff"|'''Thoracic Oncology'''
+
|colspan="4" style="background-color:#9ecae1"|'''Thoracic Oncology'''
 
|-
 
|-
−
|style="background-color:#F0F8FF"|[[Esophageal cancer]]
+
|style="background-color:#deebf7"|[[Esophageal cancer]]
−
|style="background-color:#F0F8FF"|[[Non-small cell lung cancer | Lung cancer, non-small cell (NSCLC)]]
+
|style="background-color:#deebf7"|[[Non-small cell lung cancer | Lung cancer, non-small cell (NSCLC)]]
−
|style="background-color:#F0F8FF"|[[Small cell lung cancer | Lung cancer, small cell (SCLC)]]
+
|style="background-color:#deebf7"|[[Small cell lung cancer | Lung cancer, small cell (SCLC)]]
−
|style="background-color:#F0F8FF"|[[Mesothelioma]]
+
|style="background-color:#deebf7"|[[Mesothelioma]]
 
|-
 
|-
−
|style="background-color:#F0F8FF"|[[Thymoma]]
+
|style="background-color:#deebf7"|[[Thymoma]]
−
|style="background-color:#F0F8FF"|
+
|style="background-color:#deebf7"|
−
|style="background-color:#F0F8FF"|
+
|style="background-color:#deebf7"|
−
|style="background-color:#F0F8FF"|
+
|style="background-color:#deebf7"|
 
|-
 
|-
−
|colspan="4" style="background-color:#93cdff"|'''Site-agnostic'''
+
|colspan="4" style="background-color:#9ecae1"|'''Site-agnostic'''
 
|-
 
|-
−
|style="background-color:#F0F8FF"|[[MSI-H or dMMR]]
+
|style="background-color:#deebf7"|[[MSI-H or dMMR]]
−
|style="background-color:#F0F8FF"|[[Unknown primary]]
+
|style="background-color:#deebf7"|[[Unknown primary]]
−
|style="background-color:#F0F8FF"|
+
|style="background-color:#deebf7"|
−
|style="background-color:#F0F8FF"|
+
|style="background-color:#deebf7"|
 
|-
 
|-
 
|}
 
|}
Line 142: Line 143:
 
|}
 
|}
 
{| border="1" style="text-align:center; margin-left: auto; margin-right: auto; font-weight: bold; width: 100%;"
 
{| border="1" style="text-align:center; margin-left: auto; margin-right: auto; font-weight: bold; width: 100%;"
−
!colspan="4" align="center" style="color:white; font-size:150%; background-color:#FF0D00"| '''Malignant Hematology'''
+
!colspan="4" align="center" style="color:white; font-size:150%; background-color:#de2d26"| '''Malignant Hematology'''
 
|-
 
|-
−
|colspan="4" style="background-color:#ff9e99"|'''Acute leukemias'''
+
|colspan="4" style="background-color:#fc9272"|'''Acute leukemias'''
 
|-
 
|-
−
|style="width: 25%; background-color:#FFF0F5"|[[Acute myeloid leukemia | Acute myeloid leukemia (AML)]]
+
|style="width: 25%; background-color:#fee0d2"|[[Acute myeloid leukemia | Acute myeloid leukemia (AML)]]
−
|style="width: 25%; background-color:#FFF0F5"|[[Acute promyelocytic leukemia | Acute promyelocytic leukemia (APL)]]
+
|style="width: 25%; background-color:#fee0d2"|[[Acute promyelocytic leukemia | Acute promyelocytic leukemia (APL)]]
−
|style="width: 25%; background-color:#FFF0F5"|[[B-cell acute lymphoblastic leukemia | B-cell acute lymphoblastic leukemia (B-ALL)]]
+
|style="width: 25%; background-color:#fee0d2"|[[B-cell acute lymphoblastic leukemia | B-cell acute lymphoblastic leukemia (B-ALL)]]
−
|style="width: 25%; background-color:#FFF0F5"|[[T-cell acute lymphoblastic leukemia | T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/T-LBL)]]
+
|style="width: 25%; background-color:#fee0d2"|[[T-cell acute lymphoblastic leukemia | T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/T-LBL)]]
 
|-
 
|-
−
|style="background-color:#FFF0F5"|[[CNS leukemia]]
+
|colspan="4" style="background-color:#fc9272"|'''Myeloproliferative neoplasms and myelodysplastic syndromes'''
−
|style="background-color:#FFF0F5"|[[Transplant conditioning regimens]]
 
−
|style="background-color:#FFF0F5"|
 
−
|style="background-color:#FFF0F5"|
 
 
|-
 
|-
−
|colspan="4" style="background-color:#ff9e99"|'''Myeloproliferative neoplasms and myelodysplastic syndromes'''
+
|style="background-color:#fee0d2"|[[Chronic myelogenous leukemia | Chronic myelogenous leukemia (CML)]]
 +
|style="background-color:#fee0d2"|[[Chronic myelomonocytic leukemia | Chronic myelomonocytic leukemia (CMML)]]
 +
|style="background-color:#fee0d2"|[[Essential thrombocythemia | Essential thrombocythemia (ET)]]
 +
|style="background-color:#fee0d2"|[[Hypereosinophilic syndrome| Hypereosinophilic syndrome (HES)]]
 
|-
 
|-
−
|style="background-color:#FFF0F5"|[[Chronic myelogenous leukemia | Chronic myelogenous leukemia (CML)]]
+
|style="background-color:#fee0d2"|[[Myelodysplastic syndrome]]
−
|style="background-color:#FFF0F5"|[[Chronic myelomonocytic leukemia | Chronic myelomonocytic leukemia (CMML)]]
+
|style="background-color:#fee0d2"|[[Myelofibrosis | Primary & secondary myelofibrosis]]
−
|style="background-color:#FFF0F5"|[[Essential thrombocythemia | Essential thrombocythemia (ET)]]
+
|style="background-color:#fee0d2"|[[Polycythemia vera | Polycythemia vera (PV)]]
−
|style="background-color:#FFF0F5"|[[Hypereosinophilic syndrome| Hypereosinophilic syndrome (HES)]]
+
|style="background-color:#fee0d2"|[[Systemic mastocytosis]]
 
|-
 
|-
−
|style="background-color:#FFF0F5"|[[Myelodysplastic syndrome]]
+
|colspan="4" style="background-color:#fc9272"|'''Mature B-, T-, and NK-cell neoplasms'''
−
|style="background-color:#FFF0F5"|[[Myelofibrosis | Primary & secondary myelofibrosis]]
 
−
|style="background-color:#FFF0F5"|[[Polycythemia vera | Polycythemia vera (PV)]]
 
−
|style="background-color:#FFF0F5"|[[Systemic mastocytosis]]
 
 
|-
 
|-
−
|colspan="4" style="background-color:#ff9e99"|'''Mature B-, T-, and NK-cell neoplasms'''
+
|style="background-color:#fee0d2"|[[Adult T-cell leukemia-lymphoma|Adult T-cell leukemia-lymphoma (ATLL)]]
 +
|style="background-color:#fee0d2"|[[Anaplastic large cell lymphoma|Anaplastic large cell lymphoma (ALCL)]]
 +
|style="background-color:#fee0d2"|[[Burkitt lymphoma|Burkitt lymphoma (BL) or Burkitt-like lymphoma]]
 +
|style="background-color:#fee0d2"|[[Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL) | Chronic lymphocytic leukemia (CLL/SLL)]]
 
|-
 
|-
−
|style="background-color:#FFF0F5"|[[Adult T-cell leukemia-lymphoma|Adult T-cell leukemia-lymphoma (ATLL)]]
+
|style="background-color:#fee0d2"|[[CNS lymphoma]]
−
|style="background-color:#FFF0F5"|[[Anaplastic large cell lymphoma|Anaplastic large cell lymphoma (ALCL)]]
+
|style="background-color:#fee0d2"|[[Cutaneous T-cell lymphoma|Cutaneous T-cell lymphoma (CTCL)]]
−
|style="background-color:#FFF0F5"|[[Burkitt lymphoma|Burkitt lymphoma (BL) or Burkitt-like lymphoma]]
+
|style="background-color:#fee0d2"|[[Diffuse large B-cell lymphoma|Diffuse large B-cell lymphoma (DLBCL)]]
−
|style="background-color:#FFF0F5"|[[Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL) | Chronic lymphocytic leukemia (CLL/SLL)]]
+
|style="background-color:#fee0d2"|[[Extranodal NK/T-cell lymphoma, nasal type]]
 
|-
 
|-
−
|style="background-color:#FFF0F5"|[[CNS lymphoma]]
+
|style="background-color:#fee0d2"|[[Follicular lymphoma|Follicular lymphoma (FL)]]
−
|style="background-color:#FFF0F5"|[[Cutaneous T-cell lymphoma|Cutaneous T-cell lymphoma (CTCL)]]
+
|style="background-color:#fee0d2"|[[Hairy cell leukemia|Hairy cell leukemia (HCL)]]
−
|style="background-color:#FFF0F5"|[[Diffuse large B-cell lymphoma|Diffuse large B-cell lymphoma (DLBCL)]]
+
|style="background-color:#fee0d2"|[[HIV-associated lymphoma]]
−
|style="background-color:#FFF0F5"|[[Extranodal NK/T-cell lymphoma, nasal type]]
+
|style="background-color:#fee0d2"|[[Hodgkin lymphoma|Hodgkin lymphoma (HL)]]  
 
|-
 
|-
−
|style="background-color:#FFF0F5"|[[Follicular lymphoma|Follicular lymphoma (FL)]]
+
|style="background-color:#fee0d2"|[[Hodgkin lymphoma, nodular lymphocyte-predominant|Hodgkin lymphoma, nodular lymphocyte-predominant (NLP-HL)]]
−
|style="background-color:#FFF0F5"|[[Hairy cell leukemia|Hairy cell leukemia (HCL)]]
+
|style="background-color:#fee0d2"|[[Large granular lymphocytic leukemia|Large granular lymphocytic (LGL) leukemia]]
−
|style="background-color:#FFF0F5"|[[HIV-associated lymphoma]]
+
|style="background-color:#fee0d2"|[[Light-chain (AL) amyloidosis]]
−
|style="background-color:#FFF0F5"|[[Hodgkin lymphoma|Hodgkin lymphoma (HL)]]  
+
|style="background-color:#fee0d2"|[[Mantle cell lymphoma|Mantle cell lymphoma (MCL)]]
 
|-
 
|-
−
|style="background-color:#FFF0F5"|[[Hodgkin lymphoma, nodular lymphocyte-predominant|Hodgkin lymphoma, nodular lymphocyte-predominant (NLP-HL)]]
+
|style="background-color:#fee0d2"|[[Marginal zone lymphoma|Marginal zone lymphoma (MZL)]]
−
|style="background-color:#FFF0F5"|[[Large granular lymphocytic leukemia|Large granular lymphocytic (LGL) leukemia]]
+
|style="background-color:#fee0d2"|[[Mediastinal gray-zone lymphoma|Mediastinal gray-zone lymphoma (MGZL)]]
−
|style="background-color:#FFF0F5"|[[Light-chain (AL) amyloidosis]]
+
|style="background-color:#fee0d2"|[[Multiple myeloma|Multiple myeloma (MM)]]
−
|style="background-color:#FFF0F5"|[[Mantle cell lymphoma|Mantle cell lymphoma (MCL)]]
+
|style="background-color:#fee0d2"|[[NK/T-cell lymphoma]]
 
|-
 
|-
−
|style="background-color:#FFF0F5"|[[Marginal zone lymphoma|Marginal zone lymphoma (MZL)]]
+
|style="background-color:#fee0d2"|[[Peripheral T-cell lymphoma|Peripheral T-cell Lymphoma (PTCL)]]
−
|style="background-color:#FFF0F5"|[[Mediastinal gray-zone lymphoma|Mediastinal gray-zone lymphoma (MGZL)]]
+
|style="background-color:#fee0d2"|[[Plasma cell leukemia]]
−
|style="background-color:#FFF0F5"|[[Multiple myeloma|Multiple myeloma (MM)]]
+
|style="background-color:#fee0d2"|[[Post-transplant lymphoproliferative disorder|Post-transplant lymphoproliferative disorder (PTLD)]]
−
|style="background-color:#FFF0F5"|[[NK/T-cell lymphoma]]
+
|style="background-color:#fee0d2"|[[Primary mediastinal B-cell lymphoma|Primary mediastinal B-cell lymphoma (PMBL)]]
 
|-
 
|-
−
|style="background-color:#FFF0F5"|[[Peripheral T-cell lymphoma|Peripheral T-cell Lymphoma (PTCL)]]
+
|style="background-color:#fee0d2"|[[Transformed lymphoma|Transformed lymphoma (TL)]]
−
|style="background-color:#FFF0F5"|[[Plasma cell leukemia]]
+
|style="background-color:#fee0d2"|[[Waldenström macroglobulinemia|Waldenström macroglobulinemia (WM/LPL)]]
−
|style="background-color:#FFF0F5"|[[Post-transplant lymphoproliferative disorder|Post-transplant lymphoproliferative disorder (PTLD)]]
+
|style="background-color:#fee0d2"|
−
|style="background-color:#FFF0F5"|[[Primary mediastinal B-cell lymphoma|Primary mediastinal B-cell lymphoma (PMBL)]]
+
|style="background-color:#fee0d2"|
 
|-
 
|-
−
|style="background-color:#FFF0F5"|[[Transformed lymphoma|Transformed lymphoma (TL)]]
+
|}
−
|style="background-color:#FFF0F5"|[[Transplant conditioning regimens]]
+
<span id="transplant"></span>
−
|style="background-color:#FFF0F5"|[[Waldenström macroglobulinemia|Waldenström macroglobulinemia (WM/LPL)]]
+
{| class="wikitable" style="float:right; margin-left: 5px;"
−
|style="background-color:#FFF0F5"|
+
|-
 +
|[[#top|back to top]]
 +
|}
 +
{| border="1" style="text-align:center; margin-left: auto; margin-right: auto; font-weight: bold; width: 100%;"
 +
|colspan="4" align="center" style="color:white; font-size:150%; background-color:#756bb1"|'''Transplant'''
 +
|-
 +
|style="width: 25%; background-color:#efedf5"|[[Stem cell mobilization]]
 +
|style="width: 25%; background-color:#efedf5"|[[Allogeneic HSCT conditioning regimens]]
 +
|style="width: 25%; background-color:#efedf5"|[[Autologous HSCT conditioning regimens]]
 +
|style="width: 25%; background-color:#efedf5"|[[Graft versus host disease (GVHD)]]
 
|-
 
|-
 
|}
 
|}
Line 212: Line 222:
 
|}
 
|}
 
{| border="1" style="text-align:center; margin-left: auto; margin-right: auto; font-weight: bold; width: 100%;"
 
{| border="1" style="text-align:center; margin-left: auto; margin-right: auto; font-weight: bold; width: 100%;"
−
|colspan="4" align="center" style="color:white; font-size:150%; background-color:#228B22"|'''Other Hematology'''
+
|colspan="4" align="center" style="color:white; font-size:150%; background-color:#31a354"|'''Other Hematology'''
 
|-
 
|-
−
|style="width: 25%; background-color:#F0FFF0"|[[Aplastic anemia]]
+
|style="width: 25%; background-color:#e5f5e0"|[[Aplastic anemia]]
−
|style="width: 25%; background-color:#F0FFF0"|[[Atypical hemolytic-uremic syndrome (aHUS)]]
+
|style="width: 25%; background-color:#e5f5e0"|[[Atypical hemolytic-uremic syndrome (aHUS)]]
−
|style="width: 25%; background-color:#F0FFF0"|[[Autoimmune cytopenias]]
+
|style="width: 25%; background-color:#e5f5e0"|[[Autoimmune cytopenias]]
−
|style="width: 25%; background-color:#F0FFF0"|[[Autoimmune thrombocytopenic purpura (ITP)]]
+
|style="width: 25%; background-color:#e5f5e0"|[[Autoimmune thrombocytopenic purpura (ITP)]]
 
|-
 
|-
−
|style="background-color:#F0FFF0"|[[Castleman disease]]
+
|style="background-color:#e5f5e0"|[[Castleman disease]]
−
|style="background-color:#F0FFF0"|[[Coagulopathies]]
+
|style="background-color:#e5f5e0"|[[Coagulopathies]]
−
|style="background-color:#F0FFF0"|[[Cold agglutinin disease]]
+
|style="background-color:#e5f5e0"|[[Cold agglutinin disease]]
−
|style="background-color:#F0FFF0"|[[Hemophagocytic lymphohistiocytosis (HLH)]]
+
|style="background-color:#e5f5e0"|[[Hemophagocytic lymphohistiocytosis (HLH)]]
 
|-
 
|-
−
|style="background-color:#F0FFF0"|[[Histiocytoses]]
+
|style="background-color:#e5f5e0"|[[Histiocytoses]]
−
|style="background-color:#F0FFF0"|[[Paroxysmal nocturnal hemoglobinuria (PNH)]]
+
|style="background-color:#e5f5e0"|[[Paroxysmal nocturnal hemoglobinuria (PNH)]]
−
|style="background-color:#F0FFF0"|[[Sickle cell anemia]]
+
|style="background-color:#e5f5e0"|[[Sickle cell anemia]]
−
|style="background-color:#F0FFF0"|[[Thrombotic thrombocytopenic purpura|Thrombotic thrombocytopenic purpura (TTP)]]
+
|style="background-color:#e5f5e0"|[[Thrombotic thrombocytopenic purpura|Thrombotic thrombocytopenic purpura (TTP)]]
 
|-
 
|-
−
|style="background-color:#F0FFF0"|[[Venous thromboembolism (VTE)]]
+
|style="background-color:#e5f5e0"|[[Venous thromboembolism (VTE)]]
−
|style="background-color:#F0FFF0"|
+
|style="background-color:#e5f5e0"|
−
|style="background-color:#F0FFF0"|
+
|style="background-color:#e5f5e0"|
−
|style="background-color:#F0FFF0"|
+
|style="background-color:#e5f5e0"|
 
|-
 
|-
 
|}
 
|}

Revision as of 03:06, 4 October 2017

HemOnc.org - A Free Hematology/Oncology Reference

Regimens: 4,452 Regimen variants: 6,605
Solid Tumors Malignant Heme Other Heme Transplant
Editorial Board
Disease index Drug index Regimen index General reference
Desktop Version Mobile Version Mobile shortcut Fellowship programs
If this is your first time visiting, please go to the tutorial page or just start exploring!

Links to Main Disease Pages

Solid Tumors
Breast Oncology
Breast cancer Breast cancer, HER-2 positive
Dermatologic Oncology
Melanoma Skin, basal & squamous cancer Merkel cell carcinoma
Endocrine Oncology
Germ cell tumors Neuroendocrine tumors Thyroid cancer
Gastrointestinal Oncology
Anal cancer Colon cancer Esophageal cancer Gastric cancer
Gastrointestinal stromal tumor (GIST) Hepatobiliary cancer Pancreatic cancer Rectal cancer
Genitourinary Oncology
Bladder cancer Germ cell tumors Penile cancer Prostate cancer
Renal cancer (RCC) Testicular cancer
Gynecologic Oncology
Cervical cancer Germ cell tumors Ovarian cancer Uterine cancer
Head & Neck Oncology
Head and neck cancer Thyroid cancer
Neuro-Oncology
Central nervous system (CNS) cancer Glioblastoma CNS leukemia CNS lymphoma
Pediatric Oncology
Neuroblastoma
Sarcoma
Bone cancer Ewing's sarcoma Gastrointestinal stromal tumor (GIST) Osteosarcoma
Sarcoma
Thoracic Oncology
Esophageal cancer Lung cancer, non-small cell (NSCLC) Lung cancer, small cell (SCLC) Mesothelioma
Thymoma
Site-agnostic
MSI-H or dMMR Unknown primary

back to top
Malignant Hematology
Acute leukemias
Acute myeloid leukemia (AML) Acute promyelocytic leukemia (APL) B-cell acute lymphoblastic leukemia (B-ALL) T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/T-LBL)
Myeloproliferative neoplasms and myelodysplastic syndromes
Chronic myelogenous leukemia (CML) Chronic myelomonocytic leukemia (CMML) Essential thrombocythemia (ET) Hypereosinophilic syndrome (HES)
Myelodysplastic syndrome Primary & secondary myelofibrosis Polycythemia vera (PV) Systemic mastocytosis
Mature B-, T-, and NK-cell neoplasms
Adult T-cell leukemia-lymphoma (ATLL) Anaplastic large cell lymphoma (ALCL) Burkitt lymphoma (BL) or Burkitt-like lymphoma Chronic lymphocytic leukemia (CLL/SLL)
CNS lymphoma Cutaneous T-cell lymphoma (CTCL) Diffuse large B-cell lymphoma (DLBCL) Extranodal NK/T-cell lymphoma, nasal type
Follicular lymphoma (FL) Hairy cell leukemia (HCL) HIV-associated lymphoma Hodgkin lymphoma (HL)
Hodgkin lymphoma, nodular lymphocyte-predominant (NLP-HL) Large granular lymphocytic (LGL) leukemia Light-chain (AL) amyloidosis Mantle cell lymphoma (MCL)
Marginal zone lymphoma (MZL) Mediastinal gray-zone lymphoma (MGZL) Multiple myeloma (MM) NK/T-cell lymphoma
Peripheral T-cell Lymphoma (PTCL) Plasma cell leukemia Post-transplant lymphoproliferative disorder (PTLD) Primary mediastinal B-cell lymphoma (PMBL)
Transformed lymphoma (TL) Waldenström macroglobulinemia (WM/LPL)

back to top
Transplant
Stem cell mobilization Allogeneic HSCT conditioning regimens Autologous HSCT conditioning regimens Graft versus host disease (GVHD)

back to top
Other Hematology
Aplastic anemia Atypical hemolytic-uremic syndrome (aHUS) Autoimmune cytopenias Autoimmune thrombocytopenic purpura (ITP)
Castleman disease Coagulopathies Cold agglutinin disease Hemophagocytic lymphohistiocytosis (HLH)
Histiocytoses Paroxysmal nocturnal hemoglobinuria (PNH) Sickle cell anemia Thrombotic thrombocytopenic purpura (TTP)
Venous thromboembolism (VTE)
Browse our complete index of pages

Additional Information

Created as a knowledge base for hematology & oncology providers, HemOnc.org is a collaborative wiki containing details about 100s of hematology/oncology drugs, and 1000s of antineoplastic regimens. Content is added by hematology & oncology providers, and undergoes continuous peer review.


Any information that one feels would be helpful to other oncology providers is welcome. Visit how to contribute for more details. Priorities of this project include:

  1. Creating a database of chemotherapy agents and other medications.
  2. Creating a database of chemotherapy regimens and references to primary literature (PubMed and direct links to the abstracts/full articles).
  3. Sample order sets and examples of supportive medications used with treatment regimens
  4. Aggregating useful links to existing resources by disease, such as information about prognosis, clinical calculators, staging, and patient resources.

Additional possibilities for this project may include:

  1. Creating summaries of pivotal clinical trials
  2. Establishing homepages for ongoing clinical trials that contain information and sites of participation
  3. Checklists for common clinical scenarios/diseases
  4. Creating checklists that can be used for patients starting therapy with particular regimens, such as laboratory & imaging (e.g. echocardiogram, PFTs) parameters to monitor and informed consent/discussion of side effects

The field of hematology/oncology is ever-changing, and our hope is that other people will be interested in contributing to make it an increasingly more useful resource. The rapidly evolving nature of the practice demands a more dynamic medium than existing resources can provide and would benefit from being able to be updated in real-time from virtually any computer with internet access. We believe that the familiar format of a Wiki, made popular by sites such as Wikipedia, will significantly help ease-of-use and navigation.

Retrieved from "https://hemonc.org/w/index.php?title=Editing_test_page&oldid=17711"